Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame	Description
Primary	American College of Rheumatology 20% improvement (ACR20) responder rate	12 weeks
Secondary	ACR50 responder rate	12 weeks
Secondary	ACR70 responder rate	12 weeks
Secondary	Disease Activity Score on 28-joint count (DAS28)	12 weeks
Secondary	Clinical Disease Activity Index (CDAI)	12 weeks
Secondary	Simplified Disease Activity Index (SDAI)	12 weeks
Secondary	ACR/EULAR remission criteria	12 weeks
Secondary	Adverse Events	12 weeks	number of patients with Adverse Events
Secondary	Routine Laboratory determinations	12 weeks
Secondary	Pharmacokinetics (PK) of Methotrexate and CR6086 in combination	12 weeks	Main PK endpoint: AUCinf (ng.h/mL). Area under the plasma concentration vs time curve extrapolated to infinity
Secondary	Biochemical markers	12 weeks	Serum biomarkers of disease activity
Secondary	Imaging biomarkers	12 weeks	Dynamic Contrast-Enhanced MRI (DCE-MRI)

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03163966/registered